Here, we demonstrated that the generation of a hypoxia-activated anti-PKM2 Ab can eliminate the side effects of parent Ab and improve its efficiency in selectively targeting HCC cells (Fig. 5-6). Here, PKM is linked to hepatocellular carcinoma.